Allergy Therapeutics PLC Director/PDMR Shareholding (4794T)
October 12 2017 - 9:55AM
UK Regulatory
TIDMAGY
RNS Number : 4794T
Allergy Therapeutics PLC
12 October 2017
12 October 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Director/PDMR Shareholding
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, announces
that, on 11 October 2017, Tunde Otulana, Non-Executive Director of
the Company, purchased 25,000 ordinary shares of 0.10p in the
Company ("Ordinary Shares") at a price of $0.5066 per Ordinary
Share (equivalent to 38.41p per Ordinary Share)*. Mr Otulana's
total beneficial holding now amounts to 25,000 Ordinary Shares,
which represents 0.004% of the issued share capital of the Company
to which voting rights are attached.
Notification of transactions of persons discharging managerial
responsibilities and persons closely associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------
a) Name Babatunde (Tunde) Otulana
--- ----------------- ----------------------------------
2 Reason for the notification
Acquisition of shares
--- -----------------------------------------------------
a) Position/status Non-Executive Director
--- ----------------- ----------------------------------
b) Initial Initial notification
notification
/Amendment
--- ----------------- ----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- -----------------------------------------------------
a) Name ALLERGY THERAPEUTICS PLC
--- ----------------- ----------------------------------
b) LEI
--- ----------------- ----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------
a) Description Ordinary Shares of GBP0.0001 each
of the
financial
instrument,
type of
instrument
Identification
code
--- ----------------- ----------------------------------
b) Nature Purchase of Ordinary Shares
of the
transaction
--- ----------------- ----------------------------------
c) Price(s) Price(s) Volume(s)
and volume(s) --------------- ----------
$0.5066
per Ordinary
share 25,000
--------------- ----------
--- ----------------- ----------------------------------
d) Aggregated
information
- Aggregated
volume 25,000 ordinary shares
- Price $12,665.00
--- ----------------- ----------------------------------
e) Date of 11 October 2017
the transaction
--- ----------------- ----------------------------------
f) Place of United States
the transaction
--- ----------------- ----------------------------------
This announcement contains insider information for the purposes
of Article 7 of Regulatory (EU) No596/2014.
*calculated at a rate of GBP GBP1.00 to USD $1.3189, as at
midday (BST) 11 October 2017
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBXBDGBUBBGRD
(END) Dow Jones Newswires
October 12, 2017 09:55 ET (13:55 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024